ARAF and colorectal carcinoma: These studies suggests that anti-inflammatory treatment may limit the risk of CRC by acting on the host to limit inflammation-induced dysplasia while simultaneously limiting production of carcinogenic toxins released by opportunistically pathogenic pks+ E.